内皮素受体拮抗剂治疗肺动脉高压的临床应用进展

内皮素（ET）-1是强有力的内源性血管收缩剂，在肺动脉高压的发病机制中发挥重要作用。ET受体分为两种类型：ETA和ETB。本文综述近年来非选择性ET受体拮抗剂和选择性ETA受体拮抗剂治疗肺动脉高压的临床应用进展。证明ET受体拮抗剂可以改善肺动脉高压患者的运动耐量，降低肺血管阻力，增加心输出量，改善心功能。其主要副作用是血清转氨酶增高。

Clinial application of endothelin receptor antagonists in treatment of pulmonary hypertension

Endothelin-1(ET-1) is a powerful intrinic vasoconstrictor,which plays an important role in the development of pulmonary hypertension.There are two types of ET-1 receptors,ETA and ETB.This article gives a review of the recent advancement in clinical application of non-selective and selective ET receptor antagonists in the treatment of pulmonary hypertension.Endothelin receptor antagonists have been shown to improve symptoms,exercise capacity,and hemodynamics of patients with pulmonary hypertension.The main side effect of ET receptor antagonists is the elevation of hepatic transaminase.